![]() |
Technical Data |
|
V2110-06A |
Vascular Endothelial Growth Factor, Endocrine-gland-Derived, Recombinant, Human (EG-VEGF) |
5ug 20ug |
| Growth Factors, Cytokines | Storage: -20°CShipping: RT |
|
Human endocrine gland derived vascular endothelial growth factor (EG-VEGF) is selectively expressed in steroidogenic glands and promotes growth of endocrine gland endothelium. The identification of tissue-selective angiogenic factors raises the possibility that other secreted molecules in this class exist. Consistent with such an expression pattern, the human EG-VEGF gene promoter has a potential binding site for steroidogenic factor (SF)-1, a pivotal element for steroidogenic-specific transcription. In the human ovary, the expression of EG-VEGF is temporally and spatially complementary to the expression of VEGF-A, both in the follicular and in the luteal phase, suggesting complementary and coordinated roles of these molecules in ovarian angiogenesis. Also, EG-VEGF expression correlates with vascularity in the polycystic ovary syndrome, a leading cause of infertility. Recombinant Human EG-VEGF is a single, non-glycosylated, polypeptide chain containing 86 amino acids and having a molecular mass of 9.6kD. Sequence: The sequence of the first five N-terminal amino acids was determined and was found to be Ala-Val-Ile-Thr-Gly. Dimers and Aggregates: 1% as determined by silver-stained SDS-PAGE gel analysis. Protein Content: Protein quantitation was carried out by two independent methods: 1. UV spectroscopy at 280 nm. 2. Analysis by RP-HPLC, using a calibrated solution of EG-VEGF as a Reference Standard. Biological Activity: The biological activity is determined by the dose-dependent stimulation of the proliferation of human umbilical vein endothelial cells (HUVEC) using a concentration range of 1-5ng/ml. Storage and Stability: Lyophilized powder may be stored at 4°C for short-term only. Reconstitute to nominal volume by adding sterile dH2O, 0.1% BSA or HSA and store at -20°C. Reconstituted product is stable for 12 months at -20°C. For maximum recovery of product, centrifuge the original vial prior to removing the cap. Further dilutions can be made in assay buffer. |
Source: Recombinant, Human (E. coli). Purity: 98% by RP-HPLC, FPLC, or reducing/non-reducing SDS-PAGE Silver Stain. Chromatographically purified. Endotoxin: < 0.1ng/ug (IEU/ug) Concentration: ~0.1mg/ml Form: Supplied as a lyophilized powder with no additives. Reconstitute with sterile ddH2O, 0.1% BSA or HSA. to a concentration of >0.1mg/ml Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological. |
|
1. Bv8 and endocrine gland-derived vascular endothelial growth factor stimulate hematopoiesis and hematopoietic cell mobilization. LeCouter J, Zlot C, Peale F, Proc Natl Acad Sci U S A 2004 Nov 30;101(48):16813-8 2. Differential expression of the angiogenic factor genes vascular endothelial growth factor (VEGF) and endocrine gland-derived VEGF in normal and polycystic human ovaries. Ferrara N, Frantz G, Dillard-Telm L, Peale F, Am J Pathol 2003 Jun;162(6):1881-93 3. Mouse endocrine gland-derived vascular endothelial growth factor: a distinct expression pattern from its human ortholog suggests different roles as a regulator of organ-specific angiogenesis. LeCouter J, Lin R, Zhang Z, Endocrinology 2003 Jun;144(6):2606-16 4. The endocrine-gland-derived VEGF homologue Bv8 promotes angiogenesis in the testis: Localization of Bv8 receptors to endothelial cells. LeCouter J, Lin R, Frantz G, Proc Natl Acad Sci U S A 2003 Mar 4;100(5):2685-90 5. Expression of endocrine gland-derived vascular endothelial growth factor in ovarian carcinoma. Zhang L, Yang N, Katsaros D, Toll A, Clin Cancer Res 2003 Jan;9(1):264-72 6. Endocrine gland vascular endothelial growth factor (EG-VEGF) and the hypothesis of tissue-specific regulation of angiogenesis. Ferrara N, LeCouter J, Endocr Res 2002 Nov;28(4):763-4
|
||